CBD (cannabidiol)
Sleep & Recovery · Non-psychoactive cannabinoid
Tier C+
What this is
Consumer CBD product quality varies enormously — cannabiscore/third-party testing essential. FDA has not created supplement regulatory pathway for CBD despite Farm Bill 2018. Sleep evidence is thinner than popular perception suggests; anxiolytic signal is slightly stronger. Drug-drug interactions (especially with warfarin, SSRIs, antiepileptics) are real and underappreciated.
Mechanism
Partial CB1 agonist/allosteric modulator; 5-HT1A agonist; GPR55 antagonist; anti-inflammatory; FDA-approved (Epidiolex) for rare epilepsies; non-intoxicating
Dose & route
25-300 mg/day PO (supplement range); 10-20 mg/kg/day (Epidiolex)
Citations
- https://pubmed.ncbi.nlm.nih.gov/30624194/
- https://pubmed.ncbi.nlm.nih.gov/21307846/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC6326553/
Links go to the source. If a link is dead or you want something re-checked, let me know.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.